Skip to main content

Table 5 Comparison of survival on CRRT by principal diagnosis, weight, CRRT indication, and immune status between study eras and shown over the 10 year study period

From: Pediatric continuous renal replacement therapy: have practice changes changed outcomes? A large single-center ten-year retrospective evaluation

  2004–2008 2009–2013 2004–2013
Survivor
n (%)
Survivor
n (%)
Survivor
n (%)
Principal Diagnosis Category
 Cardiac 7 (54%) 3 (27%) 10 (42%)
 Renal 4 (44%) 14 (74%) 18 (64%)
 Liver 6 (32%) 17 (46%) 23 (41%)
 Hematology/Oncology a 10 (56%) 3 (18%) 13 (37%)
 Bone marrow transplant 3 (17%) 5 (33%) 8 (24%)
 Pulmonary 4 (36%) 2 (50%) 6 (40%)
 Inborn error of metabolism 5 (100%) 7 (70%) 12 (80%)
 Sepsis 3 (30%) 2 (40%) 5 (33%)
 Neonates 8 (80%) 8 (62%) 16 (70%)
 Other b 10 (63%) 10 (77%) 20 (69%)
Weight
 0-10 kg 9 (35%) 19 (50%) 28 (44%)
 10-25 kg 13 (45%) 22 (56%) 35 (51%)
 25-50 kg 17 (49%) 13 (39%) 30 (44%)
 > 50 kg 21 (54%) 17 (50%) 38 (52%)
Indications for CRRT
 Fluid overload 31 (42%) 35 (49%) 66 (46%)
 Fluid overload & electrolyte management 12 (43%) 17 (41%) 29 (41%)
 Prevent fluid overload/provide nutrition 3 (50%) 2 (67%) 5 (56%)
 Electrolyte management 4 (57%) 4 (44%) 8 (50%)
 Other c 10 (71%) 13 (68%) 23 (70%)
Days on CRRT
 1 day 8 (47%) 5 (55%) 12 (50%)
 2–7 days 24 (42%) 34 (45%) 58 (44%)
 8–14 days 18 (50%) 12 (36%) 30 (43%)
 15–21 days 10 (53%) 11 (48%) 21 (50%)
 22–28 days 1 (17%) 7 (50%) 8 (40%)
 > 28 days 3 (25%) 7 (50%) 10 (38%)
Immune Status
 Solid organ transplant 11 (44%) 17 (52%) 28 (48%)
 Bone marrow transplant 5 (29%) 5 (36%) 10 (32%)
 Other immunocompromised 12 (48%) 11 (42%) 23 (45%)
 Not immunocompromised 32 (52%) 38 (54%) 70 (53%)
  1. ap < 0.05 comparing 2004–2008 survivors with 2009–2013 survivors
  2. bIncludes rheumatologic, gastroenterologic, multiple organ, neurologic, ingestions, hemorrhage, rhabdomyolysis, and non-accidental trauma
  3. cIncludes hemodynamic instability, hyperammonemia, ingestion, and end-stage renal disease